PPLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | PPLPHARMA | Market Cap | 21,517 Cr. | Current Price | 162 ₹ | High / Low | 226 ₹ |
| Stock P/E | 29.2 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 154 ₹ | DMA 200 | 173 ₹ |
| Chg in FII Hold | 0.51 % | Chg in DII Hold | -0.07 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 61.5 | MACD | 4.52 | Volume | 36,50,670 | Avg Vol 1Wk | 67,00,136 |
| Low price | 132 ₹ | High price | 226 ₹ | PEG Ratio | 1.31 | Debt to equity | 0.12 |
| 52w Index | 31.6 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 30.1 |
📊 Optimal Buy Price (Intraday): ₹160–163 (near DMA 50 support at ₹154)
🎯 Profit-Taking Levels: ₹168–172 (short-term resistance zone, below DMA 200 at ₹173)
🛡️ Stop-Loss / Loss Protection: ₹156–158 (below intraday support)
⏱️ Exit Strategy (If Already Holding): Exit if price fails to sustain above ₹158 with rising volume, or book profits near ₹168–172 if RSI weakens. Extend trades only if breakout volume sustains above ₹172–173.
---
### Positive
- EPS of ₹5.39 provides valuation base.
- PAT at ₹151 Cr. remains strong despite sequential decline.
- Price trading above DMA 50 (₹154), showing short-term strength.
- FII holding increased (+0.51%), reflecting foreign investor confidence.
- Debt-to-equity at 0.12 indicates low leverage risk.
- Liquidity strong with volume (36.5 lakh) supporting intraday trades.
### Limitation
- PAT declined sequentially (₹196 Cr. → ₹151 Cr.), showing earnings pressure.
- RSI at 61.5 indicates neutral-to-slightly overbought momentum.
- MACD at 4.52 shows mild bullish bias but lacks strong breakout signals.
- Current price below DMA 200 (₹173), limiting medium-term strength.
- Dividend yield at 0.09% provides negligible income support.
### Company Negative News
- Sequential PAT decline highlights earnings slowdown.
- DII holding reduced (-0.07%), showing cautious domestic sentiment.
### Company Positive News
- Quarterly profit variation (+27.4%) highlights strong year-on-year growth.
- FII holding increased (+0.51%), boosting sentiment.
- 52-week index at 31.6% shows relative price strength despite volatility.
### Industry
- Pharma sector benefits from defensive demand and long-term growth.
- Industry PE at 30.1 is aligned with PPLPHARMA’s P/E (29.2), suggesting fair valuation.
### Conclusion
PPLPHARMA is a moderately strong intraday candidate with improving momentum but earnings pressure. Best suited for disciplined trades between ₹160–172 with strict stop-loss at ₹158. Avoid aggressive positions unless strong breakout volume confirms strength above ₹173; risk remains moderate due to sequential profit decline and cautious domestic sentiment.
Would you like me to add a pharma peer benchmarking overlay (Sun Pharma, Dr. Reddy’s, Cipla, Lupin) so you can directly compare PPLPHARMA’s intraday momentum and valuation premium against sector leaders?